ProStrakan Group Chooses RelayHealth for Approved Abstral REMS Program

Published: Jan 20, 2011

(BUSINESS WIRE)--ProStrakan Group plc, an international pharmaceutical company based in the UK, has announced that it has chosen RelayHealth Pharmacy Solutions as its connectivity partner and McKesson Specialty Care Solutions to administer its U.S. Food and Drug Administration (FDA)-approved Abstral Risk Evaluation and Mitigation Strategy (REMS) program.

Back to news